Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 20

1.

Randomized, placebo-controlled trials of dichlorphenamide in periodic paralysis.

Sansone VA, Burge J, McDermott MP, Smith PC, Herr B, Tawil R, Pandya S, Kissel J, Ciafaloni E, Shieh P, Ralph JW, Amato A, Cannon SC, Trivedi J, Barohn R, Crum B, Mitsumoto H, Pestronk A, Meola G, Conwit R, Hanna MG, Griggs RC; Muscle Study Group.

Neurology. 2016 Feb 10. pii: 10.1212/WNL.0000000000002416. [Epub ahead of print]

PMID:
26865514
2.

Serum metabolomic response of myasthenia gravis patients to chronic prednisone treatment.

Sengupta M, Cheema A, Kaminski HJ, Kusner LL; Muscle Study Group.

PLoS One. 2014 Jul 17;9(7):e102635. doi: 10.1371/journal.pone.0102635. eCollection 2014.

3.

Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis?

Sanders DB, Burns TM, Cutter GR, Massey JM, Juel VC, Hobson-Webb L; Muscle Study Group.

Muscle Nerve. 2014 Apr;49(4):483-6. doi: 10.1002/mus.23944.

PMID:
23835683
4.

High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized, double-masked, controlled trial.

Lewis RA, McDermott MP, Herrmann DN, Hoke A, Clawson LL, Siskind C, Feely SM, Miller LJ, Barohn RJ, Smith P, Luebbe E, Wu X, Shy ME; Muscle Study Group.

JAMA Neurol. 2013 Aug;70(8):981-7. doi: 10.1001/jamaneurol.2013.3178.

5.

Phase II trial of methotrexate in myasthenia gravis.

Pasnoor M, He J, Herbelin L, Dimachkie M, Barohn RJ; Muscle Study Group.

Ann N Y Acad Sci. 2012 Dec;1275:23-8. doi: 10.1111/j.1749-6632.2012.06804.x.

6.

Role of disease severity, illness perceptions, and mood on quality of life in muscle disease.

Rose MR, Sadjadi R, Weinman J, Akhtar T, Pandya S, Kissel JT, Jackson CE; Muscle Study Group.

Muscle Nerve. 2012 Sep;46(3):351-9. doi: 10.1002/mus.23320.

PMID:
22907225
7.

Validation of the individualised neuromuscular quality of life for the USA with comparison of the impact of muscle disease on those living in USA versus UK.

Sadjadi R, Vincent KA, Carr AJ, Walburn J, Brooks VL, Pandya S, Kissel JT, Jackson CE, Rose MR; Muscle Study Group.

Health Qual Life Outcomes. 2011 Dec 16;9:114. doi: 10.1186/1477-7525-9-114.

8.

A randomized, pilot trial of etanercept in dermatomyositis.

Muscle Study Group.

Ann Neurol. 2011 Sep;70(3):427-36. doi: 10.1002/ana.22477. Epub 2011 Jun 17.

9.

Observational study of spinal muscular atrophy type 2 and 3: functional outcomes over 1 year.

Kaufmann P, McDermott MP, Darras BT, Finkel R, Kang P, Oskoui M, Constantinescu A, Sproule DM, Foley AR, Yang M, Tawil R, Chung W, Martens B, Montes J, O'Hagen J, Dunaway S, Flickinger JM, Quigley J, Riley S, Glanzman AM, Benton M, Ryan PA, Irvine C, Annis CL, Butler H, Caracciolo J, Montgomery M, Marra J, Koo B, De Vivo DC; Muscle Study Group; Pediatric Neuromuscular Clinical Research Network for Spinal Muscular Atrophy.

Arch Neurol. 2011 Jun;68(6):779-86. doi: 10.1001/archneurol.2010.373. Epub 2011 Feb 14.

10.

What determines quality of life in inclusion body myositis?

Sadjadi R, Rose MR; Muscle Study Group.

J Neurol Neurosurg Psychiatry. 2010 Oct;81(10):1164-6. doi: 10.1136/jnnp.2009.183863. Epub 2010 Jul 2.

PMID:
20601666
11.

Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients.

Jackson CE, Gronseth G, Rosenfeld J, Barohn RJ, Dubinsky R, Simpson CB, McVey A, Kittrell PP, King R, Herbelin L; Muscle Study Group.

Muscle Nerve. 2009 Feb;39(2):137-43. doi: 10.1002/mus.21213.

PMID:
19145653
12.

Construction of an efficient evaluative instrument for myasthenia gravis: the MG composite.

Burns TM, Conaway MR, Cutter GR, Sanders DB; Muscle Study Group.

Muscle Nerve. 2008 Dec;38(6):1553-62. doi: 10.1002/mus.21185.

PMID:
19016543
13.

Comparison of outcome measures from a trial of mycophenolate mofetil in myasthenia gravis.

Wolfe GI, Barohn RJ, Sanders DB, McDermott MP; Muscle Study Group.

Muscle Nerve. 2008 Nov;38(5):1429-33. doi: 10.1002/mus.21142.

PMID:
18949779
14.

Disease-specific measure of quality of life for myasthenia gravis.

Mullins LL, Carpentier MY, Paul RH, Sanders DB; Muscle Study Group.

Muscle Nerve. 2008 Aug;38(2):947-56. doi: 10.1002/mus.21016.

PMID:
18697209
15.

Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis.

Burns TM, Conaway MR, Cutter GR, Sanders DB; Muscle Study Group.

Muscle Nerve. 2008 Aug;38(2):957-63. doi: 10.1002/mus.21053.

PMID:
18642357
16.

Characterization of ganglionic acetylcholine receptor autoantibodies.

Vernino S, Lindstrom J, Hopkins S, Wang Z, Low PA; Muscle Study Group.

J Neuroimmunol. 2008 Jun 15;197(1):63-9. doi: 10.1016/j.jneuroim.2008.03.017. Epub 2008 May 15.

17.

A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis.

Muscle Study Group.

Neurology. 2008 Aug 5;71(6):394-9. doi: 10.1212/01.wnl.0000312373.67493.7f. Epub 2008 Apr 23.

PMID:
18434639
18.

Inclusion body myositis functional rating scale: a reliable and valid measure of disease severity.

Jackson CE, Barohn RJ, Gronseth G, Pandya S, Herbelin L; Muscle Study Group.

Muscle Nerve. 2008 Apr;37(4):473-6. doi: 10.1002/mus.20958.

PMID:
18236463
19.

Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body myositis.

Muscle Study Group.

Neurology. 2004 Aug 24;63(4):718-20.

PMID:
15326251
20.

Randomized pilot trial of betaINF1a (Avonex) in patients with inclusion body myositis.

Muscle Study Group.

Neurology. 2001 Nov 13;57(9):1566-70. Erratum in: Neurology 2002 Jan 22;58(2):334.

PMID:
11706093
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk